Abstract: Disclosed are a heterocyclic compound for an immune checkpoint inhibitor capable of blocking a VISTA signaling pathway, and a preparation method therefor and a use thereof. The compound is as represented by formula I. The compound has a novel structure, can be formulated for oral administration, overcomes the treatment defects and drug resistance of monoclonal antibody-based immune checkpoint inhibitors, can be used to prepare a small molecule inhibitor easily, and is convenient for industrial production.

Abstract: The invention discloses a compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof. The invention also discloses a preparation method of the compound and use thereof in preventing and/or treating cancer or tumor-related diseases, in particular diseases such as breast cancer, prostate cancer, lung cancer, multiple myeloma, leukemia, gastric cancer, ovarian cancer, colon cancer, liver cancer, pancreatic cancer, human glioma and the like. The compound of the invention is expected to be developed into a new generation of anticancer drugs.

Abstract: A composition containing SUMO inhibitor, and belongs to the technical field of medicine includes FXR agonist and SUMO inhibitor. In activated hepatic stellate cells, the FXR agonist does not have an effect in inhibiting the activation of hepatic stellate cells. After the FXR agonist and the SUMO inhibitor are compounded according to the present invention, the activation of hepatic stellate cells can also be inhibited for those cells under activated state. Of note, the hepatic stellate cells of an individual with hepatic fibrosis symptoms have been in an activated state, therefore a good anti-fibrotic effect cannot be achieved by using the FXR agonist alone.

Abstract: A heterocyclic urea compound, and specifically discloses an indoleamine-2,3-dioxygenase inhibitor of a heterocyclic urea compound, which solves the problems of weak curative effect and larger toxic and side effects of existing immunological therapy drugs. The invention further provides a preparation method for an indoleamine-2,3-dioxygenase inhibitor of a heterocyclic urea compound, and an application of the indoleamine-2,3-dioxygenase inhibitor of a heterocyclic urea compound or a pharmaceutically acceptable salt thereof in preparing drugs for treating or preventing tumors.

Abstract: A composition containing SUMO inhibitor, and belongs to the technical field of medicine includes FXR agonist and SUMO inhibitor. In activated hepatic stellate cells, the FXR agonist does not have an effect in inhibiting the activation of hepatic stellate cells. After the FXR agonist and the SUMO inhibitor are compounded according to the present invention, the activation of hepatic stellate cells can also be inhibited for those cells under activated state. Of note, the hepatic stellate cells of an individual with hepatic fibrosis symptoms have been in an activated state, therefore a good anti-fibrotic effect cannot be achieved by using the FXR agonist alone.

Abstract: A heterocyclic urea compound, and specifically discloses an indoleamine-2,3-dioxygenase inhibitor of a heterocyclic urea compound, which solves the problems of weak curative effect and larger toxic and side effects of existing immunological therapy drugs. The invention further provides a preparation method for an indoleamine-2,3-dioxygenase inhibitor of a heterocyclic urea compound, and an application of the indoleamine-2,3-dioxygenase inhibitor of a heterocyclic urea compound or a pharmaceutically acceptable salt thereof in preparing drugs for treating or preventing tumors.

Abstract: The disclosure relates to a method and apparatus for implementing self-adaption of cross granularity in an Optical Transport Network (OTN). The method includes: acquiring an optical interface side OTN service signal which has been processed by a frame-forming chip, and performing determination on the frame header of an Optical channel Data Unit (ODU) frame of the current level in the OTN service signal; when frame-alignment is determined to be successful, performing level-by-level de-multiplexing processing on the ODU frame of the current level to obtain cross granularities of different levels, selecting output channels for the cross granularities of different levels, performing mapping processing on the output cross granularities of different levels to form fixed rate service signals, and outputting the fixed rate service signals to back board ports, where the signals are transmitted to a cross board.

Abstract: The disclosure relates to a method and apparatus for implementing self-adaption of cross granularity in an Optical Transport Network (OTN). The method includes: acquiring an optical interface side OTN service signal which has been processed by a frame-forming chip, and performing determination on the frame header of an Optical channel Data Unit (ODU) frame of the current level in the OTN service signal; when frame-alignment is determined to be successful, performing level-by-level de-multiplexing processing on the ODU frame of the current level to obtain cross granularities of different levels, selecting output channels for the cross granularities of different levels, performing mapping processing on the output cross granularities of different levels to form fixed rate service signals, and outputting the fixed rate service signals to back board ports, where the signals are transmitted to a cross board.